Thymosin alpha-1 (Zadaxin) as an influenza vaccine adjuvant in elderly populations improved antibody responses and seroconversion rates in multiple clinical studies — established evidence for immune-boosted vaccination.
Key findingThymosin alpha-1 (Zadaxin) as an influenza vaccine adjuvant in elderly populations improved antibody responses and seroconversion rates in multiple cl
What the researchers found
Thymosin alpha-1 (Zadaxin) as an influenza vaccine adjuvant in elderly populations improved antibody responses and seroconversion rates in multiple clinical studies — established evidence for immune-boosted vaccination.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2011.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review.
Journal of preventive medicine and hygiene, 52(3), 111-5
Citation
Panatto, D; Amicizia, D; Lai, P L; Camerini, R; De Rosa, A; Gasparini, R. (2011). Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review.. Journal of preventive medicine and hygiene, 52(3), 111-5.